ArticleOncotarget2013

Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.

Mareike Roscher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.